Cable Hill Partners’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Cable Hill Partners’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,700	Closed	-$35K	–	874
2018 Q3	$35K	Sell	1,700 -300	-15%	-$7.14K	0.01%	233
2018 Q2	$60K	Buy	2,000 +1,000	+100%	+$27.2K	0.03%	178
2018 Q1	$28K	Buy	+1,000	New	+$29.9K	0.01%	285

Other funds holding DOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cable Hill Partners's DOVA Position: Q4 2018 in Review

Cable Hill Partners sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2018, closing a stake of 1,700 shares — an estimated $35K sold.

Cable Hill Partners first reported a position in DOVA in Q1 2018 and held it in 3 quarters. The position peaked at $60K in Q2 2018. 58 funds tracked by Wall St. Rank hold DOVA as of Q4 2018.

Cable Hill Partners reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Cable Hill Partners sold 1,700 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $35K.
Cable Hill Partners first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Cable Hill Partners's Dova Pharmaceuticals, Inc. Common Stock position peaked at $60K in Q2 2018.
58 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Cable Hill Partners's 13F filing for Q4 2018, filed 12 Feb 2019.